Pharma-Bio Serv, Inc.
PBSV
$0.50
$0.012.04%
OTC PK
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -8.08% | -5.35% | -14.75% | -25.46% | -36.50% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -8.08% | -5.35% | -14.75% | -25.46% | -36.50% |
| Cost of Revenue | -13.01% | -12.90% | -21.82% | -28.05% | -36.30% |
| Gross Profit | 4.21% | 15.66% | 6.19% | -18.85% | -36.98% |
| SG&A Expenses | -5.04% | -6.73% | -9.18% | -7.59% | -8.01% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.22% | -10.73% | -17.69% | -21.92% | -28.62% |
| Operating Income | 32.02% | 50.47% | 44.44% | -111.78% | -368.62% |
| Income Before Tax | 86.21% | 87.54% | 85.64% | -317.69% | -157.09% |
| Income Tax Expenses | -15.53% | -71.95% | -155.73% | -105.71% | -95.73% |
| Earnings from Continuing Operations | 84.73% | 87.08% | 89.97% | -3,403.70% | -181.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 84.73% | 87.08% | 89.97% | -3,403.70% | -181.29% |
| EBIT | 32.02% | 50.47% | 44.44% | -111.78% | -368.62% |
| EBITDA | 37.26% | 54.29% | 47.56% | -120.84% | -335.08% |
| EPS Basic | 84.79% | 87.32% | 90.19% | -2,633.33% | -181.58% |
| Normalized Basic EPS | 85.61% | 87.32% | 85.51% | -312.00% | -156.65% |
| EPS Diluted | 81.98% | 86.71% | 89.57% | -1,680.00% | -184.09% |
| Normalized Diluted EPS | 85.61% | 87.32% | 85.51% | -312.00% | -156.65% |
| Average Basic Shares Outstanding | -0.15% | -0.10% | -0.10% | -0.07% | -0.04% |
| Average Diluted Shares Outstanding | -0.13% | -0.11% | -0.11% | -0.11% | -0.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -5.54% | -6.73% | -8.96% | 0.97% | -2.23% |